The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
#EULAR2024: DMARDs
To update you on the exciting content presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to disease-modifying antirheumatic drugs (DMARDs), here.
CONGRESS #EULAR2024 | Dr. Beatriz Joven-Ibáñez presented data from a TRINETX global population study of transition risk from PsO to PsA with biologics. Assessed 1,175,000 patients with PsO. Incidence of PsA was higher in patients treated with TNFis vs ILis. #psoriasis… pic.twitter.com/Ct1wInDcDX
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024
CONGRESS #EULAR2024 | Rasmus Westermann discussed data on the risk of skin cancer in patients with PsA treated with bDMARDs. Patients treated with TNFi experienced increased risk of non-melanoma skin cancer, basal cell carcinoma, and squamous cell carcinoma. #psoriaticarthritis pic.twitter.com/1qwvryRj7T
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
CONGRESS #EULAR2024 | POSTER @edgar_wiebe presented a poster on bone mineral density (BMD) in PsO and PsA. In PsO, BMD was positively correlated with csDMARD and bDMARD use, and physical activity. In PsA, presence of diabetes and csDMARD use had a positive effect on BMD.… pic.twitter.com/9o9JPKbN0a
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
CONGRESS #EULAR2024 | POSTER: Sofia Ferreira Azevedo presented a poster on preventing PsA in patients with psoriasis. bDMARDs were found to reduce the risk for progression to PsA compared to other treatments. #psoriaticarthritis pic.twitter.com/6r31dgNBtg
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: Dr. Dafna D. Gladman presented a poster on risk of chronic kidney disease in PsA. Joint damage and daily NSAID use were associated with CKD in patients with PsA, whereas the use of MTX offered a renoprotective effect. #psoriaticarthritis pic.twitter.com/2qGWTDwiAQ
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | Dr. Gabriele De Marco discussed the use of golimumab + MTX + CS compared to only MTX + CS. PASDAS at Week 24 was not significantly different between groups. #psoriaticarthritis pic.twitter.com/RQxjUlsLBz
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content